Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 3Breast 3Thoracic 2Other 2Lymphoid 2Gynecologic 2Plasma cell 1Head & Neck 1Endocrine 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Pain 1Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ketorolac × Gynecologic × Clear all
NCT02470299 2025-05-22

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

New Mexico Cancer Research Alliance

Phase NA Completed
21 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT01670799 2020-02-27

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

New Mexico Cancer Research Alliance

Phase EARLY_PHASE1 Completed
29 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡